Alnylam Pharmace. buy BMO Capital Markets
Summary
This prediction is currently active. With a performance of 2.80%, the BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 24.06.25. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w |
---|---|
Alnylam Pharmace. | -8.032% |
iShares Core DAX® | -0.543% |
iShares Nasdaq 100 | -2.696% |
iShares Nikkei 225® | -2.863% |
iShares S&P 500 | -1.105% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren